Results And Additional Analyses From Efficacy And Safety Study Of Corthera's Relaxin In Acute Heart Failure To Be Presented At Heart Failure Congress

Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France. Marco Metra, M.D.